Programme

Contents

Programme at a glance 3

Symposia in detail 10
  The Conference features a number of high-quality symposia, each designed to attract a broad spectrum of cancer specialists.

Parallel sessions in detail 12
  The parallel sessions cover a breadth of topics, spanning the central themes of: The cancer cell and model systems; Diagnosis and therapy; Epidemiology and prevention; Information, patients and the public; Survivorship and end-of-life care; and Tumour specific research.

Workshops in detail 34
  The Conference also features a range of workshops designed to provide opportunities for development and networking.
Programme at a glance Sunday

12.15 – 14.15 The tumour microenvironment and its effect on treatment response
Hosted by Stephanie McKeown and Tracy Robson

14.20 – 14.30 Welcome address
Sir Kenneth Calman
Chair, National Cancer Research Institute, UK

Larry Norton
Memorial Sloan-Kettering Cancer Center, New York, USA

15.10 – 15.50 Role of telomeres in cancer and ageing
Maria Blasco
Spanish National Cancer Research Centre, Madrid, Spain

16.00 – 17.30 Poster Session A and Refreshment Break

17.40 – 18.20 Drugging the cancer genome: design of personalised cancer medicines
The BACR Tom Connors Lecture
Paul Workman
Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK

18.30 – 19.30 Public event and open forum: The Cancer Tales
Chaired by Sir Kenneth Calman
Chair, National Cancer Research Institute, UK
This performance of two stories from Cancer Tales, written by Nell Dunn, is based on the real-life experiences of cancer patients and their families. The play will be followed by a questions and answers forum with a panel of experts, and is free for both Conference delegates and the public to attend

19.30 – 21:00 Opening Reception and Trade Exhibition
Programme at a glance Monday

08.00 – 08.50 Workshops
- BACR educational workshop: early phase clinical trial design for non-clinicians
  Hosted by Anne Thomas
  University of Leicester, UK
- BOA ‘Meet the Professor’ workshop: cell cycle control, mechanisms and their relevance to cancer?
  Hosted by Kai Stoebber
  University College London, UK

09.00 – 09.10 Introduction to the programme
Ron Laskey
Chair, Programme Planning Committee, UK

09.10 – 09.50 Synthetic lethal approaches to the development of new therapies for cancer
Alan Ashworth
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK

09.50 – 10.30 Difficult decisions: end of life care or assisted suicide?
Ilora Finlay
Cardiff University, UK

10.30 – 11.00 Refreshment Break and Exhibition Viewing

11.00 – 12.30 Symposia
- Getting personal in anticancer drug development
  Hosted by Johann de Bono
  The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
- Societal attitudes to death and dying
  Hosted by Mike Richards¹ and Teresa Tate²
  ¹National Cancer Director (England), UK, and ²Marie Curie Cancer Care, UK
- Targeting invasion and metastases
  Hosted by Margaret Frame
  University of Edinburgh, UK

12.30 – 14.20 Poster Session B and Lunch

12.30 – 15.30 Trade Exhibition Viewing

13.00 – 14.00 Commercial workshop
- Illumina high throughput sequencing: investigations into cancer genome biology – Sponsored by Illumina
- Emerging treatment options in metastatic disease - Sponsored by Amgen
14.30 – 15.30  **Workshops**
- How to become a post-doc or a clinician scientist
- Prioritising research in the networks
- Randomised controlled trials in end of life care
- Tumour banking and access to samples debate

15.40 – 17.55  **Parallel sessions**
- From the genome to the clinic: connecting data for better health
- Hypoxia and the Warburg effect
- Improving patient care: quality assurance of psychological care
- Infection and cancer: epidemiology, biology and prevention
- Lung cancer
- New strategies for improving prognosis in breast cancer
- Paediatric tumours
- PET Imaging
- Proffered paper highlights 1
- Targeting mitosis
- Upper gastrointestinal cancers

18.00 – 18.30  **Refreshment Break**

18.30 – 19.50  **Clinical trials showcase**
*Hosted by David Cameron*
National Cancer Research Network, UK

- **Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer**
  Andrew Tutt
  Breakthrough Breast Cancer Research Unit, King’s College London Guy’s Hospital, London, UK

- **MRC OV05/EORTC 55955 Ovarian Cancer Trial of early treatment of relapse based on CA125 level alone versus delayed treatment**
  Gordon Rustin
  Mount Vernon Cancer Centre, Northwood, UK

- **Results from the MRC Coin trial of first-line therapy for advanced colorectal cancer (aCRC)**
  Tim Maughan
  Cardiff University, UK

- **Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005)**
  Christopher Nutting
  Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
19.50 – 21.00 | Drinks Reception
20.00 – 22.30 | Chairman’s Reception (by invitation)
Programme at a glance  Tuesday

08.00 – 08.50  Workshops
  o  BACR educational workshop: how do cells maintain their integrity? An introduction to DNA double strand break repair and its relevance to leukaemia
  o  BOA Workshop: all about ‘omics
  o  Novel practical designs for clinical trials
  o  Methodologies in complementary therapy research

09.00 – 09.40  Tumour suppressors and hypoxia pathways in cancer
Peter Ratcliffe
University of Oxford, UK

09.40 – 10.20  Evolution of the cancer clinical trial over three decades: problems of design, analysis, reporting and interpretation
Ian Tannock
Princess Margaret Hospital, Toronto, Canada

10.20 – 11.00  Refreshment Break and Exhibition Viewing

11.00 – 12.30  Symposia
  •  30th Anniversary of p53
    Hosted by Karen Vousden
    Beatson Institute of Cancer Research, Glasgow, UK
  •  Research priorities from a global perspective
    Hosted by Jack Cuzick
    Cancer Research UK Clinical Centre, Barts and The London, UK
  •  Therapeutic antibodies
    Hosted by Martin Glennie
    University of Southampton, UK

12.30 – 14.20  Poster Session C and Lunch

12.30 – 15.30  Trade Exhibition Viewing

13.00 – 14.00  Commercial and satellite workshops
  •  nab™ technology: advancing the treatment of breast cancer
  •  Improving clinical outcomes: focus on Venous Thromboembolism
  •  Translating genomic biomarkers to medical advantage: the integrated genomics approach
14.30 – 15.30 Workshops
- The targeted therapies nurses forum
- Data linkage and long-term follow up of clinical trials
- Career paths for post-docs

15.40 – 17.55 Parallel sessions
- Acute leukaemia
- Anti-cancer drug discovery: natural products and rational design
- Colorectal cancer: optimising screening and prevention
- High throughput sequencing and cancer genomes
- Proffered paper highlights 2
- Prostate and bladder cancer
- Radiation oncology
- Research portrayal in the media
- Senescence and autophagy as an approach to therapy
- Survivorship and late effects of treatment

17.55 – 18.25 Refreshment Break

18.30 – 19.10 Complexity of clonal architecture in childhood leukaemia: Darwin re-visited
Mel Greaves
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK

19.10 – 19.50 The Bcl-2 family in cancer development and cancer treatment
Suzanne Cory
The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Australia

20.00 – 23.00 Pfizer/BOA Excellence in Oncology Awards
(by invitation)

20.15 – 01.00 Conference Dinner and Party (ticketed event)
Programme at a glance Wednesday

08.30 – 09.30  Breakfast

09.00 – 09.50  The use of biomarkers in cancer clinical trials
   Marc Buyse
   International Drug Development Institute, Brussels, Belgium

09.50 – 10.10  Refreshment Break

10.10 – 12.25  Parallel sessions
   • Brain tumours
   • Economics of drug development and provision
   • Personalised pathology
   • Preclinical models
   • Raising awareness and promoting early diagnosis
   • Successes from the ECMC Network: early phase trials, biomarkers and imaging
   • Symptom management
   • Synthetic lethality: targeting damaged pathways
   • Tumour stroma and vasculature

12.35 – 13.15  Using mice to model cancer cures
   Gerard Evan
   UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, USA

13.15 – 13.25  Closing comments
   Sir Kenneth Calman
   Chair, National Cancer Research Institute

13.25 – 14.00  Lunch (available to take away)
Symposia in detail Monday

Getting personal in anticancer drug development
Hosted by Johann de Bono
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
- Johann de Bono
  The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
  Introduction
- Stephen Friend
  Sage Bionetworks, USA
  The need for diseases models with "commons" as a mean to share data
- Caroline Dive
  Paterson Institute for Cancer Research, Manchester, UK
  Utility of Circulating Tumour Cells (CTCs) in drug development for lung cancer
- Josep Tabernero
  Vall d'Hebron University Hospital, Barcelona, Spain
  Using biomarkers in early stage development

Societal attitudes to death and dying
Hosted by Mike Richards¹ and Teresa Tate²
National Cancer Director (England), UK, and Marie Curie Cancer Care, UK
- Mike Richards¹ and Teresa Tate²
  ¹National Cancer Director, UK, and ²Marie Curie Cancer Care, UK
  Introduction
- Allan Kellehear
  University of Bath, UK
  Dying old and alone – a preference?
- Jane Seymour
  University of Nottingham, UK
  Public attitudes to death, dying and bereavement: a synthesis of evidence
- Barbara Monroe
  St. Christopher's Hospice, London, UK
  Societal attitudes to death and dying – local engagement projects
- Mayur Lakhani
  National Council for Palliative Care and the National Coalition on End of Life Care, UK
  Making things happen: The work of the National Coalition

Targeting invasion and metastases
Hosted by Margaret Frame
University of Edinburgh, UK
- Margaret Frame
  University of Edinburgh, UK
  Introduction
- Peter Friedl
  Radboud University, Netherlands
  Imaging of the invasive process in real time
- Valerie Weaver
  University of Pennsylvania, USA
  Cell adhesion molecules and tumour dormancy in 3-dimensional systems
- Jim Norman
  Beatson Institute for Cancer Research, Glasgow, UK
  Integrin trafficking in cancer
Symposia in detail Tuesday

30th Anniversary of p53
Hosted by Karen Vousden
Beatson Institute of Cancer Research, Glasgow, UK

- **Karen Vousden**
  Beatson Institute of Cancer Research, Glasgow, UK
  - Introduction

- **Karen Vousden**
  Beatson Institute of Cancer Research, Glasgow, UK
  - Regulations and functions of p53

- **David Lane**
  University of Dundee, UK
  - Drug discovery in the p53 pathway

- **Guillermina Lozano**
  MD Anderson Center, Houston, USA
  - The Mdm2/Mdm4 complex: a rheostat for p53 activity

Research priorities from a global perspective
Hosted by Jack Cuzick
Cancer Research UK Clinical Centre, Barts and The London, UK

- **Jack Cuzick**
  Cancer Research UK Clinical Centre, Barts and The London, UK
  - Introduction

- **Eduardo Franco**
  McGill University, Montreal, Canada
  - HPV vaccination and improved screening via molecular methods: new strategies in cervical cancer prevention

- **Mitch Dowsett**
  The Institute of Cancer Research, London, UK
  - Understanding biological pathways for enhanced treatment and prevention of breast cancer

- **Peter Boyle**
  International Prevention Research Institute, Lyon, France
  - New initiatives to control tobacco

Therapeutic antibodies
Hosted by Martin Glennie
University of Southampton, UK

- **Martin Glennie**
  University of Southampton, UK
  - Introduction

- **Martin Glennie**
  University of Southampton, UK
  - Selecting targets for anti-cancer antibodies: what have we learnt so far?

- **Robert Marcus**
  King’s College Hospital, London, UK
  - Title to be confirmed

- **James Allison**
  Memorial Sloan-Kettering Cancer Center, New York, USA
  - Checkpoint blockade in tumour immunotherapy: new insights and opportunities
Parallel sessions in detail Monday

**From the genome to the clinic: connecting data for better health**
Hosted by Sir Alex Markham¹ and Julie Clifton²

¹University of Leeds, UK; and ²NCRI Consumer Liaison Group, UK

- **Sir Alex Markham¹ and Julie Clifton²**
  ¹University of Leeds, UK; and ²NCRI Consumer Liaison Group, UK
  
  **Introduction**

- **Eric Holowaty**
  Cancer Care, Ontario, Canada
  Cancer Registries and the electronic health record

- **Tjeerd van Staa**
  General Practice Research Database, UK
  Connecting from primary to secondary care: the data experience

- **Stephen Friend**
  Sage Bionetworks, USA
  Data sharing and health outcomes

**Proffered paper presentations:**

- **Marketa Zvelebil**
  Breakthrough Breast Cancer Research, London, UK
  Integration, analysis and meta-mining of data to aid disease diagnosis, prognosis and treatment response

- **Alex Walker**
  University of Nottingham, UK
  Tricyclic antidepressants protect against glioma and colorectal cancer

- **Thomas Clarke**
  University of Leeds, UK

**Hypoxia and the Warburg effect**
Hosted by Peter Ratcliffe
University of Oxford, UK

- **Peter Ratcliffe**
  University of Oxford, UK
  Introduction

- **Jacques Pouyssegur**
  Developmental Biology and Cancer Research, Nice, France
  Hypoxia and tumour metabolism: approach towards new anti-cancer targets

- **Ian Tomlinson**
  University of Oxford, UK
  Fumarate hydratase and other genetic insights into tumour metabolism

- **Gregg Semenza**
  Johns Hopkins University School of Medicine, USA
  Regulation of glucose and energy metabolism by Hypoxia-Inducible Factor 1

**Proffered paper presentations:**

- **Christopher Ricketts**
  University of Oxford, UK Renal Molecular Oncology Group, Medical & Molecular Genetics, University of Birmingham, UK
  Genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD
Brijesh Madhok  
University of Leeds, UK  
Inhibition of pyruvate dehydrogenase kinase activity promotes apoptosis in colorectal cancer cells

Sashidar Yeluri  
Leeds Institute of Molecular Medicine, University of Leeds & St James’s University Hospital, UK  
Lactase dehydrogenase-5 is an independent prognostic factor in colorectal cancer: implication for future therapies

Improving patient care: quality assurance of psychological care  
Hosted by Michael Sharpe  
University of Edinburgh, UK

Michael Sharpe  
University of Edinburgh, UK  
Introduction

Jane Walker  
University of Edinburgh, UK  
SMaRT quality assurance: making sure the treatment given is the treatment intended

Amanda Ramirez  
Guy’s, King’s and St Thomas’ School of Medicine, London, UK  
Maintaining the quality of a complex behavioural intervention to promote early presentation of cancer in a randomised controlled trial

John Norrie  
Robertson Centre for Biostatistics, University of Glasgow, UK  
‘Quality’ issues in complex intervention randomised controlled trials

Proffered paper presentations:

Caroline Burgess  
Institute of Psychiatry/King’s College London, London, UK  
Training health professionals to deliver an intervention to promote early presentation of breast cancer: a pilot study in the NHS Breast Screening Programme

Eleanor Mann  
Kings College London, UK  
Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment

Galina Velikova  
University of Leeds, UK  
Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial
Infection and cancer: epidemiology, biology and prevention
Hosted by Lawrence Young
University of Birmingham, UK

- **Lawrence Young**
  University of Birmingham, UK
  **Introduction**

- **Charles Rabkin**
  National Cancer Institute, USA
  Molecular epidemiology of infection-related cancer

- **Thomas Schulz**
  Hannover Medical School, Germany
  Role of KSHV infection in the pathogenesis of sarcoma and lymphoma

- **Jean Crabtree**
  Leeds Institute for Molecular Medicine, University of Leeds, UK
  *Helicobacter pylori* infection and gastric cancer: from cause to cure

**Proffered paper presentations:**

- **Simon Chanas**
  University of Birmingham, UK
  Merkel cell polyomavirus in Merkel carcinoma: pilot project to develop biomarkers for validation in a subsequent clinical trial

- **Farhad Mashayekhi**
  University of Guilan, Rasht, Iran, Islamic Republic of
  Association of *Helicobacter pylori* vacA genotype with gastric cancer in northern Iran

- **Richard Shaw**
  University of Liverpool, UK
  Host-viral epigenetic interactions in HPV16-mediated oropharyngeal cancer

**Lung cancer**
Hosted by Michael Cullen
Queen Elizabeth Hospital, Birmingham, UK

- **Michael Cullen**
  Queen Elizabeth Hospital, Birmingham, UK
  **Introduction**

- **Aman S Coonar**
  Papworth Hospital, Cambridge, UK
  Video-assisted thoracic surgery and its place in lung cancer management

- **Frances Shepherd**
  Princess Margaret Hospital, Toronto, Canada
  Targeted therapy for advanced NSCLC: two steps forward and one step back?

- **Jean-Charles Soria**
  Institut de Cancérologie Gustave Roussy, Paris, France
  Biomarkers and the future of chemotherapy in non-small cell lung cancer

**Proffered paper presentations:**

- **Linda Sharp**
  National Cancer Registry Ireland, Cork, Ireland
  The financial costs and consequences of cancer for patients and their families: a postal survey of patients with breast, lung, and prostate cancer in Ireland
Henrik Møller  
King's College London, UK  
Intensity of radical resection for lung cancer in relation to survival outcomes in England

Alex Chacko  
Queen’s University Belfast, UK  
The mitochondrial ATP transporter VDAC1 /Porin is required for TRAIL-induced apoptosis in non-small cell lung cancer

New strategies for improving prognosis in breast cancer  
Hosted by Ian Smith  
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK

Ian Smith  
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
Introduction

John Robertson  
University of Nottingham, UK
Auto-antibodies in breast cancer: a new diagnostic tool?

Stephen Johnston  
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
Combined targeted therapies in breast cancer

Robert Coleman  
Weston Park Hospital, University of Sheffield, UK
Bone targeted therapy: modifying the soil to prevent metastatic seeding

Proffered paper presentations:

Jason S Carroll  
University Cancer Research UK; Cambridge Research Institute, Cambridge, UK
BACR/AstraZeneca Frank Rose Young Scientist Award
Understanding how pioneer factors regulate Oestrogen receptor function in breast cancer cells

Darran O’Connor  
University College Dublin, Ireland
The cocaine and amphetamine-regulated transcript (CART) is an independent prognostic factor in lymph node-negative breast cancer and predicts tamoxifen response

Neil Jelly  
University of Lincoln, UK
Anti-stem cell factor enhances the effect of Anthracycline and Taxane chemotherapy in chemoresistant breast cancer cell lines
Paediatric tumours
Hosted by Pamela Kearns
University of Birmingham, UK

- **Pamela Kearns**
  University of Birmingham, UK
  *Introduction*

- **Nick Goulden**
  Royal Hospital for Children and University of Bristol, UK
  *Minimal residual disease in acute lymphoblastic leukaemia*

- **Peter Ambros**
  Children's Cancer Research Institute, Vienna, Austria
  *Genetics of neuroblastoma*

- **Sue Burchill**
  Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds
  *The clinical impact of fusion genes in paediatric sarcomas*

Proffered paper presentations:

- **Matthew Murray**
  Medical Research Council Cancer Cell Unit, Cambridge, UK
  Malignant germ cell tumours display conserved microRNA (miRNA) profiles resulting in global changes in expression of mRNA targets

- **Catriona Parker**
  University of Manchester, UK
  Significant improvement in the outcome of children with ALL: result of the international randomised ALLR3 study

- **Seema Alexander**
  University of Lincoln, USA CR-UK Children's Cancer Group, Paterson Institute of Cancer Research, Manchester, UK
  Rac2 and asparaginyl endopeptidase regulates invasion in pre-B acute lymphoblastic leukaemia

PET Imaging
Hosted by Paul Marsden
Guy’s, King’s and St Thomas’ School of Medicine, London, UK

- **Paul Marsden**
  Guy’s, King’s and St Thomas’ School of Medicine, London, UK
  *Introduction*

- **Sibylle Ziegler**
  Technical University of Munich, Germany
  Basic principles and instrumentation for positron emission tomography

- **Stefano Fanti**
  University of Bologna, Policlinico, Italy
  Positron emission tomography - but not fludeoxyglucose

- **Roland Haubner**
  University of Innsbruck, Austria
  Non-invasive tracer techniques to characterise angiogenesis

Proffered paper presentations:

- **Martin Christlieb**
  CRUK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
  Developments in imaging hypoxia: new tracers and data modelling
- Catherine Kelly
  CRUK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
  A method for quantifying the kinetics of hypoxia tracers using multicellular tumour spheroids

- Rehan Ali
  CRUK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
  Using mathematical modelling to gain new insights into how tumour cells respond to hypoxia-selective PET tracers

Proffered paper highlights 1
Hosted by Arnie Purushotham
King’s College London, UK

- Alison Young
  St James’s Institute of Oncology, Leeds, UK
  Factors influencing adjuvant treatment choices in stage I seminoma: the patients’ perspective

- Juliet Gray
  University of Southampton, UK
  Combining peptide vaccination with immunostimulatory monoclonal antibodies provides potent immunotherapy in neuroblastoma

- Victoria Coupland
  King’s College London, UK
  Does place of death from lung, colorectal, breast, and prostate cancer vary between ethnic groups?

- Scott Morgan
  Institute of Cancer Research, Surrey, UK
  Benefit of radiotherapy dose escalation in localised prostate cancer with respect to expression of intrinsic markers of hypoxia

- Shahneen Sandhu
  Royal Marsden NHS Foundation Trust, Surrey, UK
  Pharmacokinetic and pharmacodynamic Phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition

- David Sebag-Montefiore
  On behalf of the National Cancer Research Institute and the 2nd Anal Cancer Trial Management Group, University College Clinical Trials Unit, London, UK
  The second anal cancer trial (ACT2): a randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus

- Paul Ghaneh
  Liverpool CR-UK Cancer Centre and Liverpool Cancer Trials Unit, UK
  ESPAC-3(v2): a multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma
John Burn¹, John Mathers¹, Anne-Marie Gerdes¹, Marie-Luise Bisgaard², D Gareth Evans³, Diana Eccles⁴, Annika Lindblom⁵, Finlay Macrae⁶, Eamonn Maher⁷, Jukka-Pekka Mecklin⁸, Gabriela Moeslein⁹, Sylviane Olschwang¹⁰, Raj Ramesar¹¹, Hans Vasen¹², Juul Wijnen¹³, Gail Barker¹, Faye Elliott¹⁴, Henry Lynch¹⁵, D Timothy Bishop¹⁴
¹Newcastle University, UK; ²University of Copenhagen, Denmark; ³St Mary’s Hospital, Manchester, UK; ⁴University of Southampton, UK; ⁵Karolinska Hospital, Stockholm, Sweden; ⁶The Royal Melbourne Hospital, Melbourne, Australia; ⁷Birmingham Women’s Hospital, UK; ⁸Jyväskylä Central Hospital, Finland; ⁹St. Josefs-Hospital Bochum-Linden, Germany; ¹⁰Institut Paoli Calmettes, Marseille, France; ¹¹University of Cape Town, South Africa; ¹²Foundation for Detection of Hereditary Tumours, Leiden, Netherlands; ¹³Leiden University Medical Center, Netherlands; ¹⁴University of Leeds, UK; ¹⁵Creighton University School of Medicine, Omaha, USA
CAPP2 long term follow up: aspirin protects against hereditary cancer

Discussion

Targeting mitosis
Hosted by Ashok Venkitaraman
University of Cambridge, UK

- Ashok Venkitaraman
  University of Cambridge, UK
  Introduction

- Andrea Musacchio
  IFOM-IEO Campus, Italy
  Small molecule inhibitors of mitotic progression

- Robert Wilkinson
  Astra Zeneca, UK
  Probing the mechanism of novel drugs targeted to mitosis in pre-clinical studies

- Johann de Bono
  The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
  Early clinical studies with anti-mitotic agents

Proffered paper presentations:

- Maria Thanasaoula
  CRUK-MRC Gray Institute for Radiation Oncology and Biology, Oxford, UK
  p53 prevents entry into mitosis with uncapped telomeres

- Maciej A Kaliszczyk
  Imperial College London, UK
  Physicochemical and pharmacological determinants of the efficacy of a novel series of CDK7 inhibitors

- Gareth Williams
  University College London, UK
  Loss of a FOXO3A-dependent cell cycle checkpoint for DNA replication origins sensitises cancer cells to CDC7 inhibitors

Upper gastrointestinal cancers
Hosted by David Cunningham¹ and John Neoptolemos²
¹Royal Marsden Hospital, Sutton, UK and ²University of Liverpool, UK

- David Cunningham
  Royal Marsden Hospital, Sutton, UK
  Introduction
Joerg Hoheisel  
German Cancer Research Center (DKFZ), Heidelberg, Germany  
Functional genomics and proteomics in pancreatic cancer research

Krish Ragunath  
Nottingham University Hospitals NHS Trust, UK  
Evidence base of prevention in upper gastrointestinal cancer

Martyn Caplin  
The Royal Free Hospital, London, UK  
Advances in the management of neuroendocrine tumours

Proffered paper presentations:

John Bridgewater  
University College London, UK  
Gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer (ABC): results of a multicentre, randomised phase III trial (the UK ABC-02 trial)

Rachael Barlow  
Cardiff University, UK  
Randomised controlled trial of early enteral nutrition versus conventional management in patients undergoing major resection for upper gastrointestinal cancer

Nigel Jamieson  
University of Glasgow, UK  
A microRNA prognostic signature for pancreatic ductal adenocarcinoma
Parallel sessions in detail Tuesday

**Acute leukaemia**
Hosted by Tony Green\(^1\) and Tessa Holyoake\(^2\)
\(^1\)University of Cambridge, UK; and \(^2\)University of Glasgow, UK

- **Tony Green\(^1\) and Tessa Holyoake\(^2\)**
  \(^1\)University of Cambridge, UK; and \(^2\)University of Glasgow, UK
  
  Introduction

- **Jan Cools**
  University of Leuven, Belgium
  
  Molecular genetics of T-cell acute lymphoblastic leukaemia

- **Charles Mullighan**
  St Jude Children's Research Hospital, Memphis, USA
  
  Genomic profiling of B-progenitor acute lymphoblastic leukaemia

- **Alan Burnett**
  Cardiff University, UK
  
  The impact of cytogenetic and molecular information on decision making in AML

**Proffered paper presentations:**

- **Shobha Kudva**
  University of Manchester, UK
  
  Prediction of HLA-DRB1-restricted CD4\(^+\) T cell epitopes in the childhood ALL-associated TEL-AML1 fusion oncoprotein: population coverage, and design of heteroclitic peptides

- **Kim Orchard**
  SUHT, Southampton, UK
  
  Targeted radiotherapy with an anti-CD66 monoclonal antibody prior to haematopoietic stem cell transplantation: therapy intensification without toxicity

- **Thomas Dunwell**
  University of Birmingham, UK
  
  Genome-wide epigenetic analysis of childhood acute lymphoblastic leukaemia

**Anti-cancer drug discovery: natural products and rational design**
Hosted by Ian Collins
The Institute of Cancer Research, Sutton, UK

- **Ian Collins**
  The Institute of Cancer Research, Sutton, UK
  
  Introduction

- **Nicolas Winssinger**
  Université Louis Pasteur, Strasbourg, France
  
  Diversity oriented synthesis based on natural product scaffolds

- **Barry Wilkinson**
  Biotica, Cambridge, UK
  
  Introduction Lead optimisation of rapamycin mTOR inhibitors through biosynthetic engineering

- **Mark Searcey**
  School of Chemical Sciences & Pharmacy, University of East Anglia, UK
  
  Design, synthesis and investigation of antitumour agents based on natural products
Proffered paper presentations:

- **CR Ireson**
  - Cancer Research Technology Discovery Laboratories, Wolfson Institute for Biomedical Research, London, UK
  - A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth *in vivo*

- **Wolfgang Link**
  - Spanish National Cancer Centre (CNIO), Madrid, Spain
  - Image based pathway analysis of FOXO regulation leads to the discovery of therapeutic targets and small molecule inhibitors for anticancer therapy

- **Patrick Eyers**
  - University of Sheffield, London, UK
  - A biochemical and chemical genetic analysis of Aurora and Polo-like kinase inhibitors

**Colorectal cancer: optimising screening and prevention**

Hosted by Bob Steele
Ninewells Hospital and Medical School, Dundee, UK

- **Bob Steele**
  - Ninewells Hospital and Medical School, Dundee, UK
  - Introduction

- **Graeme Young**
  - Flinders University, Adelaide, Australia
  - Optimising population screening for colorectal cancer

- **Annie Anderson**
  - University of Dundee, UK
  - Colorectal cancer screening: an underdeveloped opportunity for promoting lifestyle change?

- **Richard Logan**
  - University of Nottingham, UK
  - Adenoma prevention trials - where next?

Proffered paper presentations:

- **Donald Maxwell Parkin**
  - Queen Mary, University of London, UK
  - The fraction of colorectal cancer attributable to lifestyle and environmental factors in the UK in 2005

- **Christian von Wagner**
  - University College London, London, UK
  - Inequalities in colorectal cancer screening participation: a neighbourhood-level analysis of inner and outer London areas

- **Taina Taskila**
  - Primary Care Clinical Sciences, University of Birmingham, UK
  - Factors affecting attitudes towards colorectal cancer screening in the primary care population
High throughput sequencing and cancer genomes
Hosted by Andy Futreal
Wellcome Trust Sanger Institute, Hinxton, UK

- Andy Futreal
  Wellcome Trust Sanger Institute, Hinxton, UK
  Introduction

- Bruno Clement
  Institut national de la santé et de la recherche médicale (INSERM), France
  Hepatocellular cancer and genomes

- Stacey Gabriel
  Broad Institute, Massachusetts Institute of Technology, Cambridge, USA
  Comprehensive cancer genome characterisation by sequencing

Proffered paper presentations:

- Tarek Abdel-Fatah
  School of Molecular Medical Sciences and Nottingham University Hospital Trust, University of Nottingham, UK
  High resolution array Comparative Genomic Hybridization (aCGH) of breast carcinoma identifies Mouse Double Minutes 4 (Mdm4) as one of the early genetic changes in breast cancer development: Mdm4 is a new independent prognostic and predictive marker

- Salwati Shuib
  School Department of Medical and Molecular Genetics, University of Birmingham, UK
  Analysis of copy number alterations in familial and sporadic clear cell renal cell carcinoma with high resolution SNP arrays

- Juliet Kenicer
  Edinburgh Cancer Research Centre, the University of Edinburgh, UK
  A transcriptomic and genomic investigation into taxane resistant breast cancer

Proffered paper highlights 2
Host to be confirmed

- Zuzana Bencokova
  CR-UK/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
  Sensitisation of hypoxic tumour cells through inhibition of PARP is oxygen dependent and correlates with decreased homologous recombination

- Debbie Cunningham
  University of Birmingham, UK
  Differential phosphoproteomics of fibroblast growth factor signalling: identification of Src-mediated phosphorylation events

- Patricia Muller
  The Beatson institute for Cancer Research, Glasgow, UK
  Mutant p53 regulates invasion via integrins and EGFR

- Gareth Inman
  The Beatson Institute for Cancer Research, Glasgow, UK
  Downregulation of Disabled-2 switches TGF-beta from a tumour suppressor to a tumour promoter
o Simon Gayther
University Department of Gynaecological Oncology, UCL EGA Institute for Women’s Health, University College London, London, UK
A genome-wide association study identifies a novel ovarian cancer susceptibility locus on chromosome 9p22

o Joan Kyula
Queen’s University, Belfast, UK
ADAM-17 is a key regulator of ErbB survival response in colorectal cancer

o NingNing Li
University of Nottingham, UK
Fbxw7 (hCDC4) E3- Ubiquitin Ligase Receptor: lineage potential and its commitment to cancer

Prostate and bladder cancer
Hosted by Noel Clarke
Christie NHS Foundation Trust, Manchester, UK

- Noel Clarke
University of Manchester, UK
Introduction

- Freddie Hamdy
University of Oxford, UK
Screening for prostate cancer

- David Dearnaley
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
The management of high risk localised prostate cancer

- Vijay Ramani
Christie NHS Foundation Trust, Manchester, UK
Surgical and oncological outcomes following cystectomy for transitional cell cancer

- Richard Cowan
Christie NHS Foundation Trust, Manchester, UK
Techniques for bladder preservation for muscle invasive bladder cancer

- Gert Attard
Drug Development Unit, Institute of Cancer Research, Royal Marsden Hospital, Surrey, UK
ACP McElwain Prize: Castration-Resistant Prostate Cancer (CRPC)

Proffered paper presentations:

- Imran Ahmad
Beatson Institute for Cancer Research, Glasgow, UK
FGFR3 mutation is not the initiating mutation in urothelial cell cancer

- Ros Eeles
The Institute of Cancer Research, Sutton, Surrey, UK
Identification of multiple genetic variants which predispose to prostate cancer by genome-wide association in the PRACTICAL international consortium
Radiation oncology
Hosted by Gillies McKenna
Gray Institute for Radiation Oncology and Biology, Oxford, UK
- **Gillies McKenna**
  Gray Institute for Radiation Oncology and Biology, Oxford, UK
  Introduction
- **Kaye Williams**
  University of Manchester, UK
  Hypoxic targets for radiotherapy
- **Ruth Muschel**
  University of Oxford, UK
  Utilisation of the pre-existing vessels in cancer metastasis
- **John Humm**
  Memorial Sloan-Kettering Cancer Center, New York, USA
  Imaging the tumour microenvironment by PET

Proffered paper presentations:
- **Sebastian Serres**
  University of Oxford, UK
  Early detection of brain metastasis using novel MRI contrast agent targeting VCAM-1
- **Veerle Kersemans**
  Gray Institute for Radiation Oncology and Biology, Oxford, UK
  Micro-CT imaging for anatomical referencing in PET and SPECT: radiation dose, biological damage and image quality
- **Katherine Vallis**
  University of Oxford, Gray Institute for Radiation Oncology and Biology, UK
  γH2AX: a target for imaging and systemic radiation therapy

Research portrayal in the media
Hosted by Frances Balkwill
Bart’s and The London School of Medicine and Dentistry, UK
- **Frances Balkwill**
  Bart’s and The London School of Medicine and Dentistry, UK
  Introduction
- **Nicholas Hillier**
  The Academy of Medical Sciences, London, UK
  Hype, hope and hybrids: science, policy and media perspectives of the Human Fertilisation and Embryology Bill
- **Geoff Watts**
  Freelance science and medical writer and broadcaster, UK
  Seeing things from both sides
- **Ruth Francis**
  Nature Publishing Group, London, UK
  Research portrayal in the media – translation from abstract to media
- **Sara Candy**
  Wellcome Trust, London, UK
  The Wellcome Monitor of public awareness, knowledge, interest and attitudes to biomedical science
- **Discussion**
Senescence and autophagy as an approach to therapy
Hosted by Sharon Tooze
Cancer Research UK London Research Institute, UK

- **Sharon Tooze**
  Cancer Research UK London Research Institute, UK
  Introduction
- **Kevin Ryan**
  Beatson Institute for Cancer Research, Glasgow, UK
  Autophagy in the control of tumour cell death
- **Marja Jäättelä**
  Danish Cancer Society, Institute of Cancer Biology, Copenhagen, Denmark
  Lysosomal involvement in cell death and cancer
- **John Cleveland**
  Scripps Research Institute, Jupiter, Florida, USA
  The role of the autophagy pathway in the development and maintenance of Myc-driven lymphoma
- **Masashi Narita**
  Cancer Research UK London Research Institute, UK
  Autophagy in oncogene-induced senescence

Proffered paper presentations:
- **Madhu Basetti**
  Cancer Research UK Cambridge Research Institute, Cambridge, UK
  Choline metabolism in cellular senescence, quiescence and transformation: a 1H NMR based metabolomics study
- **Patricia Roxburgh**
  The Beatson Institute for Cancer Research, Glasgow, UK
  Inhibition of MDM2: a safe strategy in the presence of mutant p53
- **Owen Sansom**
  The Beatson Institute for Cancer Research, Glasgow, UK
  β-Catenin induced senescence progresses to urothelial cell carcinoma with PTEN mutation

Survivorship and late effects of treatment
Hosted by Jane Maher
Macmillan Cancer Support, UK

- **Jane Maher**
  Macmillan Cancer Support, UK
  Introduction
- **Flora Van Leeuwen**
  Netherlands Cancer Institute, The Netherlands
  Second malignancy after chemotherapy and radiotherapy
- **Gill Levitt**
  Great Ormond Street Hospital, London, UK
  Chronic illness after cancer treatment: lessons from childhood cancer survivors
- **Craig Earle**
  Dana-Farber Cancer Institute, Boston, USA
  Caring for cancer survivors

Proffered paper presentations:
- **Farhad Mashayekhi**
  Islamic Azad University, Tonekabon, Iran, Islamic Republic of
  An immunohistochemical study of eukaryotic initiation factor (eIF4E) expression in brain tumour
Michelle McRobbie  
University of Oxford, UK  
Genetic pathways for the prediction of the effects of ionising radiation: low dose radiosensitivity and risk to normal tissue after radiotherapy

Nada Khan  
University of Oxford, UK  
Late effects associated with treatments for breast, colorectal and prostate cancer: a matched cohort study using the General Practice Research Database and National Cancer Intelligence Network
Parallel sessions in detail Wednesday

**Brain tumours**
Hosted by Susan Short
University College Hospital, London, UK

- **Susan Short**  
  University College Hospital, London, UK
  Introduction

- **Rossella Galli**  
  Stem cell Research Institute, Milan, Italy  
  Functional and molecular characterisation of cancer stem cells from brain tumours

- **Walter Stummer**  
  University of Dusseldorf, Germany  
  Issues in the surgical therapy of malignant gliomas

- **Anca Grosu**  
  University of Freiburg, Germany  
  PET imaging and glioma

**Proffered paper presentations:**

- **Talal Fael Al-Mayhani**  
  University of Cambridge, UK  
  NG2 expression identifies a cell population capable of maintaining tumour growth in glioblastoma

- **Simone Wilkins**  
  University of Liverpool, UK  
  Vascularity in regions of highest choline predicts progression in low grade astrocytomas

- **Mausam Singhera**  
  University College London, UK  
  Outcome in a 2-year cohort of brain metastases patients treated in a specialist multi-disciplinary clinic at UCLH

**Economics of drug development and provision**
Hosted by Sir Kenneth Calman\(^1\) and David Ardon\(^2\)
\(^1\)University of Glasgow, UK; and \(^2\)NCRI Consumer Liaison Group

- **Sir Kenneth Calman\(^1\) and David Ardon\(^2\)**  
  **Introduction**

- **Alison Clough**  
  The Association of the British Pharmaceutical Industry, London, UK  
  Life and medicines: price and value

- **Elisabeth George**  
  National Institute for Health and Clinical Excellence, London, UK  
  Appraising cancer drugs at the National Institute for Clinical and Health Excellence

- **David Gillen**  
  Pfizer, UK  
  The challenge for the pharmaceutical industry in the 21st century: discovery, development and access to medicines in a distrustful environment

- **Martin Gore**  
  The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK  
  Title to be confirmed
Proffered paper presentations:
- **Timothy Yap**
  Royal Marsden Hospital, Sutton, UK
  First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-Chemokine Ligand 2 (CCL2/MCP-1) in patients with advance solid tumours
- **David Blakey**
  AstraZeneca, Macclesfield, UK
  Identification of a human antibody 3.19.3 that inhibits ANG-2 function leading to significant anti-tumour activity, both alone and in combination with VEGF inhibitors, in a panel of tumour xenograft models
- **Barbara Delage**
  Institute of Cancer, Barts and the London, London, UK
  Novel anticancer drug combinations exploiting arginine depletion with ADI-PEG 20 in the treatment of ASS1-negative malignant mesothelioma
- **Discussion**

**Personalised pathology**
Hosted by Philip Quirke
University of Leeds, UK
- **Philip Quirke**
  University of Leeds, UK
  Introduction
- **Alberto Bardelli**
  University of Turin, Italy
  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
- **Tim Maughan**
  Cardiff University, UK
  Molecular selection of therapy in colorectal cancer: COIN and FOCUS 3 trials
- **Susan Richman**
  University of Leeds, UK
  Prognostic and predictive value of KRAS and BRAF mutation status and its heterogeneous nature in aCRC
- **Adrian Jubb**
  University of Oxford, UK
  Predicting benefit from anti-VEGF therapy

Proffered paper presentations:
- **Carol Walker**
  School of Cancer Studies, Liverpool, UK
  Prognostic significance of MGMT promoter methylation in glioblastomas treated with temozolomide and radiotherapy
- **Gillian Smith**
  University of Dundee, Scotland, UK
  Novel mutations in the K-Ras oncogene: implications for personalised medicine in the treatment of colorectal cancer
Steven Walker
Almac Diagnostics, Northern Ireland, UK
The detailed molecular analysis of formalin-fixed paraffin embedded (FFPE) wild-type or mutant KRAS colorectal primaries with the aims of identifying transcripts and pathways of relevance to Cetuximab sensitivity and/or KRAS mutational status

Preclinical models
Hosted by Alan Clarke
Cardiff University, UK

Alan Clarke
Cardiff University, UK
Introduction

Jos Jonkers
Netherlands Cancer Institute, Amsterdam, The Netherlands
Preclinical models of mammary cancer

Bart Vanhaesebroeck
Barts and The London School of Medicine, London, UK
Preclinical dissection of the phosphoinositide 3-kinase pathway

Gerard Evan
UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, USA
Dissecting the tumours and its microenvironment in vivo

Proffered paper presentations:

Min Li
Baylor College of Medicine, Houston, Texas, USA
Spindle assembly checkpoint, chromosomal instability, and cancer

Owen Sansom
The Beatson Institute, Glasgow, UK
Crypt stem cells as the cells-of-origin of intestinal cancer

Qi Zeng
Institute of Molecular and Cell Biology, Singapore
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice

Raising awareness and promoting early diagnosis
Hosted by Amanda Ramirez
Guy’s, King’s and St Thomas’ School of Medicine, London, UK

Amanda Ramirez
Guy’s, King’s and St Thomas’ School of Medicine, London, UK
Introduction

David Lyon
Castlefields Health Centre, Runcorn, UK
Healthy communities collaborative: a community-based intervention to promote early presentation of cancer

Jane Wardle
University College London, UK
Measuring public awareness of cancer

Lindsay Forbes
Guy’s, King’s and St Thomas’ School of Medicine, London, UK
A health professional-delivered one-to-one intervention to promote early presentation in breast cancer: a randomised controlled trial
Proffered paper presentation:

- **Ruth Jack**
  King’s College London, UK
  Breast cancer incidence, treatment and survival in ethnic groups in South East England

- **Lindsay Forbes**
  Guy’s, King’s and St Thomas’ School of Medicine, London, UK
  A systematic review of interventions to increase cancer awareness and promote early presentation

- **Discussion**

Showcasing the successes from the ECMC Network: early phase trials, biomarkers and imaging

Hosted by Sally Burtles
Cancer Research UK, UK

- **Sally Burtles**
  Cancer Research UK, UK
  Introduction

- **Udai Banerji**
  The Institute of Cancer Research, UK
  Showcasing The Institute of Cancer Research and The Royal Marsden Experimental Cancer Medicine Centre

- **James Brenton**
  Cancer Research UK Cambridge Research Institute, UK
  Showcasing the Cambridge Experimental Cancer Medicine Centre

- **Christian Ottensmeier**
  University of Southampton, UK
  Showcasing the Southampton Experimental Cancer Medicine Centre

- **Will Steward**
  University of Leicester, UK
  Showcasing the Leicester Experimental Cancer Medicine Centre

- **Dion Morton**
  University of Birmingham, UK
  Showcasing the Birmingham Experimental Cancer Medicine Centre

- **Alan Burnett**
  University of Cardiff, UK
  Showcasing the Cardiff Experimental Cancer Medicine Centre

- **Tim Illidge**
  University of Manchester, UK
  Showcasing the Manchester Experimental Cancer Medicine Centre

Symptom management

Hosted by Mike Bennett
University of Lancaster, UK

- **Mike Bennett**
  University of Lancaster, UK
  Introduction
Mike Bennett  
University of Lancaster, UK  
Patient-based educational interventions: evidence and implementation

Stein Kaasa  
Norwegian University of Science & Technology, Trondheim, Norway  
Assessing cancer pain with new technologies

Joanne Droney  
St Joseph’s Hospice, London, UK  
Impact of pharmacogenomics on cancer pain management

Proffered paper presentations:

Linda Sharp  
National Cancer Registry Ireland, Cork, Ireland  
Associations between the financial impact of cancer and depression, anxiety and stress in individuals with breast, lung and prostate cancer

Jane B Hopkinson  
University of Southampton, UK  
A feasibility study: a mixed methods exploratory phase II cluster randomised trial to investigate the effectiveness of the ‘Macmillan Approach to Weight loss and Eating difficulties’ (MAWE)

Alan O’Kane  
Ninewells Hospital, Dundee, UK  
Assessing the effects of implementing the MASCC (Multinational Association of Supportive Care in Cancer) Antiemetic Guideline on the severity of nausea and vomiting following platinum chemotherapy
Synthetic lethality: targeting damaged pathways
Hosted by Thomas Helleday
CRUK- MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK

- **Thomas Helleday**
  CRUK- MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
  - Introduction

- **Thomas Helleday**
  University of Oxford, UK
  - Exploiting synthetic lethality in DNA repair for cancer therapy

- **Toshiyasu Taniguchi**
  Fred Hutchinson Cancer Research Center, USA
  - Secondary mutation of BRCA1/2 as a mechanism of drug resistance in BRCA1/2-mutated cancer

- **Ester Hammond**
  University of Oxford, UK
  - Exploiting hypoxia for anti-cancer therapy using a synthetic context lethality approach

**Proffered paper presentations:**

- **Madeleine Hewish**
  Institute of Cancer Research, London, UK
  - Complementary RNA interference and compound screens to identify novel therapeutic targets for mismatch repair deficient cancers

- **Sarah Martin**
  Institute of Cancer Research, London, UK
  - DNA polymerases as potential therapeutic targets for DNA mismatch repair deficient cancers

- **Mohammed Mohammed**
  University of Nottingham, UK
  - Development of human apurinic/apyrimidinic endonuclease (APE1) inhibitors for cancer therapy

Tumour stroma and vasculature
Hosted by Clare Isacke
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK

- **Clare Isacke**
  Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
  - Introduction

- **Janine Erler**
  The Institute of Cancer Research, London, UK
  - Exploring hypoxia-mediated tumour progression
  - *BACR Translational Research Award*

- **Luigi Naldini**
  Vita-Salute San Raffaele University, Milan, Italy
  - New effectors and therapeutic targets in the tumour-stroma interaction

- **William Stallcup**
  Burnham Institute for Medical Research, La Jolla, USA
  - NG2 proteoglycan in tumour vascularisation and progression
Proffered paper presentations:

- **Jae Hong Im**  
  CRUK- MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, UK  
  Vascular response during metastasis is organ-specific and regulated by host angiopoietin-2

- **Hagen Kulbe**  
  Institute of Cancer, London, UK  
  The chemokine receptor CXCR4 and its ligand CXCL12 sustain a cell-autonomous network in ovarian cancer

- **Abigail Welford**  
  University of Sheffield, UK  
  Macrophages and tumour revascularisation following treatment with vascular disrupting agents
The tumour microenvironment and its effect on treatment response: The Cancer Recognised Research Group in Northern Ireland (CRRG) Workshop
12.15 – 14.15
Hosted by Stephanie McKeown and Tracy Robson
The Cancer Recognised Research Group (CRRG) in Northern Ireland Workshop is funded and sponsored by the Northern Ireland R&D office. Its main purpose is to highlight the cancer research effort in Northern Ireland through presentations by young investigators in key research areas.

- **Margaret Ashcroft**
  Department of Translational Medicine and Therapeutics, University College London, UK
  Targeting the HIF pathway as a therapeutic approach to cancer

- **Louise Ming, Maxwell Omabe, Christopher A Mitchell, Jenny Worthington, Stephanie R McKeown**
  Biomedical Science Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
  Does hypoxia play a role in the failure of androgen ablation therapy for prostate cancer?

- **Anita Yakkundi¹, Andrea Valentine¹, Martin O’Rourke¹, Michelle Hookham¹, Hayder Dyer¹, David Waugh², Tim Harrison³, Ian James³, Graham Cotton³, David Hirst¹, Tracy Robson¹**
  ¹School of Pharmacy, Queen’s University Belfast, Northern Ireland, UK; ²Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland, UK; ³Almac Discovery, Craigavon, Northern Ireland, UK
  FKBPL and its 24mer peptide derivative inhibit angiogenesis and metastases by targeting CD44

- **Philip Dunne¹, Jennifer R McDaid¹, Jayne Loughery¹, Jayne C Boyer², C Stephen Downes¹, Rosann A Farber² and Colum P Walsh¹**
  ¹School of Biomedical Sciences, University of Ulster, Northern Ireland, UK; ²Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, North Carolina, USA
  MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea

- **Nyree Crawford, Keara Redmond, Niamh Buckley, Paul Mullan**
  Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, Northern Ireland, UK
  TBX2 drives the proliferation of breast cancer cells through repression of an EGR1-dependent signalling program
Workshops & debates in detail Monday

**BACR educational workshop: early phase clinical trial design for non-clinicians**
08.00 – 08.50
Hosted by Anne Thomas
University of Leicester, UK
- **Bruno Morgan**
  University of Leicester, UK
  Introducing imaging biomarkers into clinical studies
  Bruno Morgan will give a broad overview of the difficulties of introducing imaging biomarkers into clinical studies, with examples of successes and failures, ethical considerations, data problems and consistency.
- **Anne Thomas**
  University of Leicester, UK
  Pragmatic design of phase I clinical studies
  Anne Thomas will then focus on the practicalities of tissue and blood sampling from the patients; nurse and ethics committee perspective.

**BOA ‘Meet the Professor’ workshop: cell cycle control, mechanisms and their relevance to cancer?**
08.00 – 08.50
Hosted by Kai Stoeber
University College London, UK

**Illumina high throughput sequencing: investigations into cancer genome biology**
13.00 – 14.00
Hosted by Illumina
This seminar will include two talks from customers using the Genome Analyzer Next Generation Sequencer showing the latest applications relevant to cancer research - examples could include mRNA-seq, CHIP-seq, small RNA, genome sequencing for rearrangements/gene fusions, methylation sequencing. There will also be a talk from an Illumina representative sharing the workflow and capability of the system and the latest roadmap of output and applications for 2009.

**Emerging treatment options in metastatic disease**
13.00 – 14.00
Hosted by Amgen
Metastatic disease represents a large patient population. Common tumours include breast and colorectal cancer. We are presenting important data in both KRAS wild type colorectal cancer patients receiving first and second line chemotherapy combined with Panitumumab and Denosumab, a RANK ligand inhibitor, in breast cancer patients with bone metastases.

Randomised phase 3 study of Panitumumab with FOLFOX compared to FOLFOX alone as first-line treatment for metastatic colorectal cancer
Speaker to be confirmed

Randomised phase 3 study of Panitumumab with FOLFIRI compared FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
Marc Peeters, University Hospital Ghent, Belgium

Randomised phase 3 study of Denosumab compared to Zoledronic Acid in the Treatment of Bone Metastases in patients with Breast Cancer
Speaker to be confirmed
How to become a post-doc or a clinician scientist
14.30 – 15.30
Hosted by Sally Leevers¹, Guillermina Lozano², Bart Vanhaesebroeck³ and Charlie Swanton¹
¹Cancer Research UK London Research Institute, UK; ²MD Anderson Center, Houston, USA; ³Barts and The London School of Medicine, London, UK

Securing ‘the right’ postdoc position to go to after your PhD, is an important next step in your scientific career and can be a daunting task! This workshop will explore the various issues to think about when choosing potential labs to postdoc in, as well as providing advice on how to go about getting the position that you want! The issues discussed should be relevant to PhD students doing non-clinical PhDs and to clinical fellows considering clinician scientist positions.

Prioritising research in the networks
14.30 – 15.30
Hosted by David Cameron
National Cancer Research Network, UK

This workshop will look at the role of the National Cancer Research Network (NCRN) in clinical cancer research in the UK. The NCRN is part of the NHS National Institute for Health Research: a Department of Health funded virtual enterprise dedicated to establishing the NHS as an internationally recognised centre of research excellence. Being part of this large family of clinical research networks and research funders brings big advantages and some responsibilities, and we will discuss how this affects individual researchers.

In particular, we will focus on the following areas:

1. How to ensure your research project is eligible for access to NCRN and other NHS resources
2. How NCRN/NCRI prioritises research nationally
3. How local networks prioritise which research they will do
4. Latest information from the Department of Health about how research costs are covered in terms of what needs to come from the research grant and what can be covered in the NHS/NCRN

Randomised controlled trials in end of life care
14.30 – 15.30
Hosted by Anthony Byrne¹ and Gary Young²
¹Marie Curie Hospice and Wales Cancer Trials Unit, Penarth, UK; ²TBC

The randomised controlled trial has been championed as a ‘gold standard’ provider of evidence for assimilation into evidence-based practice. This has had a strong influence on the development of clinical guidelines and commissioning of care. Such an approach has been challenged in the context of evaluating complex interventions and in settings where trials conduct is challenging.

This workshop will explore and debate the role of the randomised controlled trial in the palliative care setting. In particular it will focus on:

1. The challenge of evidence: specifically the grades of reliability of research evidence required for guideline development and commissioning of treatment.
2. The methodological and trials conduct opportunities to respond to those challenges using the RCT model in palliative care and end of life care.
3. The importance of pragmatic and meaningful outcomes which directly reflect patient benefit in this setting.

The workshop will take account of previous experience of RCTs in palliative care settings and refer to the current NIHR palliative care portfolio. Following the
presentations, the workshop will be opened to the floor for discussion.

Speakers/panel include:
Dr Fergus Macbeth, Director of the Centre for Clinical Practice, National Institute for Health and Clinical Excellence (NICE), UK
Professor Jane Blazeby, Professor of Surgery and Director of the MRC ConDuCT methodology hub, University of Bristol, UK
Professor Ian Tannock, Daniel E Bergsagel Professor of Medical Oncology, University of Toronto, Canada

**Tumour banking and access to samples debate**
14.30 – 15.30
Hosted by Philip Quirke
University of Leeds, UK
Workshops & debates in detail

**Novel practical designs for clinical trials**
07.55-08.55
Hosted by Rhian Gabe
Medical Research Council Clinical Trials Unit, London, UK
- **Marc Buyse**
  International Drug Development Institute Inc, Massachusetts, USA
  Randomised phase II trials: are they really better?
- **Andrew Stone**
  AstraZeneca, UK
  Latest developments in phase II design
- **Mahesh Parmar**
  Medical Research Council Clinical Trials Unit, London UK
  Multi-arm, multi-stage clinical trial designs

**BACR educational workshop: how do cells maintain their integrity?**
An introduction to DNA double strand break repair and its relevance to leukaemia
08.00-08.50
Hosted by Elaine Willmore
Northern Institute for Cancer Research, University of Newcastle upon Tyne, London, UK

Double strand breaks in DNA are potentially lethal. Cells have many ways of responding to insults to their DNA, from signalling pathways that tell the cell that DNA damage has happened, to activation of repair proteins to help restore the DNA. Often these repair pathways become dysfunctional, and this can lead to the genomic instability that is a hallmark of cancer cells.

Elaine Willmore will explain the basics of one of the fast components of double strand break repair (non homologous end joining), and describe some of the alterations in this pathway that occur in chronic and acute leukaemia. Claire Seedhouse (Nottingham University) will describe another double strand repair pathway (homologous recombinational repair) and explain how changes of activity of proteins in this pathway contribute to drug resistance in acute myeloid leukaemia.

**BOA Workshop: all about ‘omics**
08.00-08.50
Hosted by the British Oncological Association

**Methodologies in complementary therapy research**
08.00-08.50
Hosted by Andrew Ritchie
NCRI Complementary Therapy Clinical Studies Development Group, London, UK

This ‘how to’ workshop session has been structured to engage and introduce laboratory scientists and oncologists to the field of complementary therapy research, highlight where conventional ‘robust’ methodologies may and may not be appropriate, give an overview of challenges associated with this research and show where successful studies have been funded and published.
nab™ technology : advancing the treatment of breast cancer
12.30 – 14.00
Hosted by Abraxis Bioscience

International breast cancer experts will review the current breast cancer treatment landscape including novel taxanes and their impact in the management of metastatic breast cancer patients. Additionally, the faculty panel will discuss and present relevant clinical case studies that focus on current treatment management challenges in daily practice.

Agenda:
Introduction
Taxanes in the treatment of metastatic breast cancer
Improving clinical outcomes in metastatic breast cancer
Clinical case studies in metastatic breast cancer
Panel discussion

Learning objectives:
• Review current treatments in metastatic breast cancer
• Discuss novel taxanes for the treatment of metastatic breast cancer
• Discuss the management of metastatic breast cancer through case study reviews

Translating genomic biomarkers to medical advantage: the integrated genomics approach
13.00 – 14.00
Hosted by Affymetrix

The ability to interrogate the human genome using whole-genome analysis tools, such as microarrays, has altered and enhanced our approach to studying complex diseases such as cancer. Combining genomic information such as gene expression and gene regulation with genotype and copy number data has proven to be an effective means of achieving focused discovery and faster validation in cancer studies. Leading scientists and clinical researchers are increasingly using Affymetrix’ integrated microarray solutions, which include the GeneChip Exon 1.0 ST, SNP 6.0 and miRNA arrays to facilitate their path from biomarker discovery to medical utility.

This workshop will help you as a research scientist, clinical researcher, or clinician to understand how scientists at the cutting edge of cancer research are successfully applying Affymetrix technology to accelerate their integrated genomics studies. You will also hear how their discoveries are being translated to powerful medical tools that positively impact the care and treatment of cancer.

Lunch and refreshments will be provided.

More information available from: http://www.affx.com/forms/NCRiworkshop
Venous thromboembolism (VTE) is a condition that encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). Among patients who survive, VTE is associated with significant long-term complications (e.g., recurrent VTE, postthrombotic syndrome, chronic leg ulcers, and chronic thromboembolic pulmonary hypertension).

Guidelines from the American Society of Clinical Oncology and the European Society of Medical Oncology recommend a proactive approach to VTE management in oncology patients. There is now a significant window of opportunity for this situation to improve, as our understanding of the risk factors for VTE, preventative modalities, and treatment of VTE has grown. Although some limitations remain to be overcome with current assessment, prevention, and treatment paradigms, even full institution of current, evidence-based, guideline-recommended modalities would substantially reduce the burden of VTE on patients, providers, and society.

In this highly interactive educational workshop utilizing audience response system technology and clinical cases, recognized experts will be invited to provide a fairbalanced, evidence-based review of recent landmarks in our understanding of the genesis of VTE, the pathophysiologic progression of disease from triggering events to long-term complications, diagnostic modalities, and recent evidence from clinical trials that support a proactive approach to disease avoidance.

The workshop will be of interest to oncologists, oncology pharmacists, oncology nurses and other healthcare professionals involved in the care of patients at risk for venous thromboembolism.
Data linkage and long-term follow up of clinical trials
14.30-15.30
Hosted by David Forman¹ and David Cameron²
¹National Cancer Intelligence Network (NCIN), UK; ²National Cancer Research Network (NCRN), UK

The long-term follow-up of patients recruited into clinical trials is of enormous value in understanding the late consequences of treatment. This is, however, a time consuming and resource intensive process when carried out by trials offices on a trial by trial basis. This Workshop will consider how linkage between clinical trial patient datasets and routine NHS data sources held within the NCIN National Cancer Data Repository offers the potential to provide such follow-up in a rapid and cost efficient manner. Results from early pilots using this process, including the MRC CLASICC and CR07 studies, will be presented together with protocols for the iBreast and other similar trials.

The Targeted Therapies Nurses Forum
14.30 – 15.30
Hosted by Lynette Lane¹ and Lynda Pyle²
¹Velindre Cancer Centre, Cardiff, UK; and ²Royal Marsden Hospital, London, UK

This workshop aims to highlight common side effects and their management for patients receiving targeted therapies, focusing on those drugs used in renal and gastrointestinal stromal tumour (GIST) cancers. These drugs are extending peoples lives and have altered patients’ outlook and life expectations. Using Maslow’s theory on hierarchy of needs, we aim to develop a nursing tool, to enhance patients’ quality of life.

- **Lynette Lane**
  Velindre Cancer Centre, Cardiff, UK
  Introduction

  Breakout groups
  Each table will discuss one of the following side effects:
  1. Skin
  2. Fatigue
  3. GI disturbances
  4. Hypertension and hypothyroidism
  5. Compliance, expectations and attitudes to taking oral therapies

- **Linda Pyle**
  Royal Marsden Hospital, London, UK
  Discussion, feedback and summary